ECSP11011134A - Anticuerpos humanos de alta afinidad contra pcsk9 - Google Patents
Anticuerpos humanos de alta afinidad contra pcsk9Info
- Publication number
- ECSP11011134A ECSP11011134A EC2011011134A ECSP11011134A ECSP11011134A EC SP11011134 A ECSP11011134 A EC SP11011134A EC 2011011134 A EC2011011134 A EC 2011011134A EC SP11011134 A ECSP11011134 A EC SP11011134A EC SP11011134 A ECSP11011134 A EC SP11011134A
- Authority
- EC
- Ecuador
- Prior art keywords
- high affinity
- human antibodies
- antibodies against
- affinity human
- small
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
- C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
- C07K16/1282—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Clostridium (G)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56911—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/195—Assays involving biological materials from specific organisms or of a specific nature from bacteria
- G01N2333/33—Assays involving biological materials from specific organisms or of a specific nature from bacteria from Clostridium (G)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S424/00—Drug, bio-affecting and body treating compositions
- Y10S424/809—Drug, bio-affecting and body treating compositions involving immunoglobulin or antibody fragment, e.g. fab', fv, fc, heavy chain or light chain
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Diabetes (AREA)
- Physics & Mathematics (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Virology (AREA)
Abstract
Un anticuerpo humano o fragmento de unión a antígeno de un anticuerpo humano que se une específicamente e inhibe la proproteína convertasa subtilisina/kexina de tipo 9 humana (hPCSK9) caracterizado por la capacidad de reducir el colesterol LDL en suero en 40-80% durante un período de 24, 60 ó 90 días con respecto a los niveles previos a la dosificación, con una reducción pequeña o nula del colesterol HDL en suero y/o con un efecto pequeño o no medible sobre la función hepática, como se determina por las medidas de ALT y AST.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12248208P | 2008-12-15 | 2008-12-15 | |
US21056609P | 2009-03-18 | 2009-03-18 | |
US16875309P | 2009-04-13 | 2009-04-13 | |
US21813609P | 2009-06-18 | 2009-06-18 | |
US24913509P | 2009-10-06 | 2009-10-06 | |
US26177609P | 2009-11-17 | 2009-11-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP11011134A true ECSP11011134A (es) | 2011-07-29 |
Family
ID=41668268
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EC2011011134A ECSP11011134A (es) | 2008-12-15 | 2011-06-15 | Anticuerpos humanos de alta afinidad contra pcsk9 |
Country Status (44)
Families Citing this family (275)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
US20130072665A1 (en) * | 2007-08-23 | 2013-03-21 | Simon Mark Jackson | Antigen binding proteins to proprotein convertase subtilisin kexin type 9 (pcsk9) |
JO3672B1 (ar) * | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
KR20120027055A (ko) * | 2009-06-26 | 2012-03-20 | 리제네론 파라마큐티칼스 인코포레이티드 | 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체 |
US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
EP2792236B2 (en) | 2009-07-08 | 2023-03-22 | Kymab Limited | Animal models and therapeutic molecules |
US8518405B2 (en) | 2009-10-08 | 2013-08-27 | The University Of North Carolina At Charlotte | Tumor specific antibodies and uses therefor |
CN102639150A (zh) * | 2009-10-30 | 2012-08-15 | 默沙东公司 | Ax213和ax132 pcsk9拮抗剂和变体 |
AR079336A1 (es) * | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
JO3274B1 (ar) | 2009-12-24 | 2018-09-16 | Regeneron Pharma | أجسام مضادة بشرية للبروتين 4 المشابه لأجيوبيوتين البشري |
SG183867A1 (en) * | 2010-03-11 | 2012-10-30 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
ES2667100T3 (es) * | 2010-08-02 | 2018-05-09 | Macrogenics, Inc. | Diacuerpos covalentes y sus usos |
US9845362B2 (en) | 2010-10-08 | 2017-12-19 | The University Of North Carolina At Charlotte | Compositions comprising chimeric antigen receptors, T cells comprising the same, and methods of using the same |
JO3756B1 (ar) | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
SG191219A1 (en) * | 2010-12-22 | 2013-07-31 | Genentech Inc | Anti-pcsk9 antibodies and methods of use |
AR084938A1 (es) * | 2011-01-28 | 2013-07-10 | Sanofi Sa | Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes |
EP2481758A1 (en) * | 2011-01-28 | 2012-08-01 | Sanofi | Human antibodies to PSCK9 for use in methods of treating particular groups of subjects (11566) |
EP2650016A1 (en) | 2011-01-28 | 2013-10-16 | Sanofi | Human antibodies to PSCK9 for use in methods of treatment based on particular dosage regimens (11565) |
SG10201609665PA (en) | 2011-02-25 | 2017-01-27 | Chugai Pharmaceutical Co Ltd | FcɣRIIb-SPECIFIC Fc ANTIBODY |
US8337530B2 (en) | 2011-03-09 | 2012-12-25 | Zimmer Spine, Inc. | Polyaxial pedicle screw with increased angulation |
AR088782A1 (es) | 2011-04-29 | 2014-07-10 | Sanofi Sa | Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes |
JOP20200043A1 (ar) * | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
WO2012170807A2 (en) | 2011-06-10 | 2012-12-13 | Medimmune, Llc | Anti-pseudomonas psl binding molecules and uses thereof |
JO3412B1 (ar) | 2011-06-17 | 2019-10-20 | Regeneron Pharma | أجسام مضادة ل angptl3 واستخداماتها |
US20140161821A1 (en) * | 2011-07-14 | 2014-06-12 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
AR087305A1 (es) * | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
AU2012308797B2 (en) | 2011-09-16 | 2017-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9) |
AR087715A1 (es) * | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
AU2012311288B2 (en) | 2011-09-19 | 2017-08-17 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
EP2761008A1 (en) | 2011-09-26 | 2014-08-06 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
JP6322411B2 (ja) | 2011-09-30 | 2018-05-09 | 中外製薬株式会社 | 複数の生理活性を有する抗原の消失を促進する抗原結合分子 |
ITPC20110013U1 (it) | 2011-10-07 | 2013-04-08 | Giovanni Merli | Struttura di protezione superiore veicoli. |
SI2776065T1 (sl) * | 2011-11-07 | 2020-10-30 | Medimmune Limited | Kombinacijske terapije z uporabo molekul, ki vežejo anti-Pseudomonas Psl in PcrV |
CA3233142A1 (en) | 2011-11-30 | 2013-06-06 | Chugai Seiyaku Kabushiki Kaisha | Drug containing carrier into cell for forming immune complex |
US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
CN104220460A (zh) | 2011-12-08 | 2014-12-17 | 安姆根有限公司 | 激动人lcat抗原结合蛋白和它们在疗法中的用途 |
WO2013112438A1 (en) | 2012-01-23 | 2013-08-01 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-ang2 antibodies |
LT2809681T (lt) * | 2012-01-31 | 2019-02-11 | Regeneron Pharmaceuticals, Inc. | Antikūnai prieš asic1 ir jų panaudojimas |
US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
MY172730A (en) | 2012-03-16 | 2019-12-11 | Regeneron Pharma | Histidine engineered light chain antibodies and genetically modified non-human animals for generating the same |
MX2014011047A (es) | 2012-03-16 | 2015-04-08 | Regeneron Pharma | Ratones que producen proteinas de union a un antigeno con caracteristicas de union dependientes del ph. |
KR102459666B1 (ko) | 2012-03-16 | 2022-10-27 | 리제너론 파마슈티칼스 인코포레이티드 | pH-민감성 면역글로불린 서열을 발현하는 비-사람 동물 |
GB2502127A (en) | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
US20130281355A1 (en) * | 2012-04-24 | 2013-10-24 | Genentech, Inc. | Cell culture compositions and methods for polypeptide production |
EA039663B1 (ru) * | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
US9255154B2 (en) * | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
BR112014031310A2 (pt) * | 2012-06-15 | 2017-07-25 | Genentech Inc | anticorpos anti-pcsk9, formulações, dosagem e métodos de uso |
US9540449B2 (en) * | 2012-08-13 | 2017-01-10 | Regeneron Pharmaceuticals, Inc. | Anti-PCSK9 antibodies with pH-dependent binding characteristics |
JO3462B1 (ar) | 2012-08-22 | 2020-07-05 | Regeneron Pharma | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها |
CA2882272C (en) | 2012-08-24 | 2023-08-29 | Chugai Seiyaku Kabushiki Kaisha | Fc.gamma.riib-specific fc region variant |
EP2703008A1 (en) * | 2012-08-31 | 2014-03-05 | Sanofi | Human antibodies to PCSK9 for use in methods of treating particular groups of subjects |
EP2703009A1 (en) | 2012-08-31 | 2014-03-05 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
EP2706070A1 (en) | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
SI3081249T1 (sl) | 2012-11-21 | 2021-03-31 | Amgen Inc. | Naprava za dajanje zdravila |
US10766960B2 (en) | 2012-12-27 | 2020-09-08 | Chugai Seiyaku Kabushiki Kaisha | Heterodimerized polypeptide |
US20150335615A1 (en) * | 2013-01-04 | 2015-11-26 | Toshihisa Kawai | Cholesterol-lowering compounds in combination with lipid metabolism-altering compounds of non-absorbable sugars, compounds that convert nh3 to nh4+, or hydrogen-generating compounds for the treatment of high cholesterol and inflammation |
WO2014107739A1 (en) * | 2013-01-07 | 2014-07-10 | Eleven Biotherapeutics, Inc. | Antibodies against pcsk9 |
AR095196A1 (es) | 2013-03-15 | 2015-09-30 | Regeneron Pharma | Medio de cultivo celular libre de suero |
CA2906508A1 (en) * | 2013-03-15 | 2014-09-25 | Amgen, Inc. | Human antigen binding proteins that bind to proprotein convertase subtilisin kexin type 9 |
CA2904725C (en) | 2013-03-15 | 2022-04-12 | Amgen Inc. | Drug cassette, autoinjector, and autoinjector system |
WO2014149699A1 (en) | 2013-03-15 | 2014-09-25 | Eli Lilly And Company | Bifunctional protein |
JP6768501B2 (ja) | 2013-03-15 | 2020-10-14 | アムゲン・インコーポレーテッド | 薬物カセット、自動注入機、および自動注入機システム |
US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
WO2014149357A1 (en) | 2013-03-22 | 2014-09-25 | Amgen Inc. | Injector and method of assembly |
EP2982689B1 (en) | 2013-04-02 | 2020-08-26 | Chugai Seiyaku Kabushiki Kaisha | Fc region variant |
US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
TWI682780B (zh) * | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
US10111953B2 (en) * | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
EP2810955A1 (en) | 2013-06-07 | 2014-12-10 | Sanofi | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
KR20160024906A (ko) * | 2013-06-07 | 2016-03-07 | 사노피 바이오테크놀로지 | Pcsk9의 억제제를 투여함에 의한 죽상경화증의 억제 방법 |
ES2901400T3 (es) * | 2013-06-07 | 2022-03-22 | Regeneron Pharma | Métodos para inhibir la ateroesclerosis administrando un inhibidor de PCSK9 |
EP2862877A1 (en) | 2013-10-18 | 2015-04-22 | Sanofi | Methods for inhibiting atherosclerosis by administering an inhibitor of PCSK9 |
WO2014209384A1 (en) | 2013-06-28 | 2014-12-31 | Amgen Inc. | Methods for treating homozygous familial hypercholesterolema |
WO2015049517A2 (en) | 2013-10-01 | 2015-04-09 | Kymab Limited | Animal models and therapeutic molecules |
JP6846931B2 (ja) | 2013-10-11 | 2021-03-24 | サノフィ・バイオテクノロジー | 高脂血症を処置するためのpcsk9阻害剤の使用 |
PL3060275T3 (pl) | 2013-10-24 | 2019-12-31 | Amgen Inc. | Wstrzykiwacz i sposób montażu |
EP3060281B1 (en) | 2013-10-24 | 2019-01-30 | Amgen Inc. | Drug delivery system with temperature-sensitive control |
TW202017595A (zh) * | 2013-11-12 | 2020-05-16 | 法商賽諾菲生物技術公司 | 使用pcsk9抑制劑之給藥療程 |
EP3882273A1 (en) | 2013-11-12 | 2021-09-22 | Sanofi Biotechnology | Dosing regimens for use with pcsk9 inhibitors |
BR112016014072B1 (pt) * | 2013-12-17 | 2023-12-26 | Kling Biotherapeutics B.V. | Anticorpo isolado, sintético ou recombinante humano, ou uma parte funciona do mesmo, molécula de ácido nucleico isolado, vetor, composição, uso de um anticorpo ou parte funcional, ou uma molécula de ácido nucleico ou um vetor e, métodos para produzir um anticorpo ou parte funcional, e para determinar se céuluas aml ou células de linfoma ou células de mieloma múltiplo ou células b de linfoma não hodgkin estão presentes em uma amostra |
US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US9034332B1 (en) | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
US9023359B1 (en) | 2014-07-15 | 2015-05-05 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US8992927B1 (en) | 2014-07-15 | 2015-03-31 | Kymab Limited | Targeting human NAV1.7 variants for treatment of pain |
US8986691B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US9051378B1 (en) | 2014-07-15 | 2015-06-09 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US8883157B1 (en) | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9067998B1 (en) | 2014-07-15 | 2015-06-30 | Kymab Limited | Targeting PD-1 variants for treatment of cancer |
US9017678B1 (en) | 2014-07-15 | 2015-04-28 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US9045548B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision Medicine by targeting rare human PCSK9 variants for cholesterol treatment |
DE202014010499U1 (de) | 2013-12-17 | 2015-10-20 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
US8980273B1 (en) | 2014-07-15 | 2015-03-17 | Kymab Limited | Method of treating atopic dermatitis or asthma using antibody to IL4RA |
US9914769B2 (en) | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
US9045545B1 (en) | 2014-07-15 | 2015-06-02 | Kymab Limited | Precision medicine by targeting PD-L1 variants for treatment of cancer |
US8986694B1 (en) | 2014-07-15 | 2015-03-24 | Kymab Limited | Targeting human nav1.7 variants for treatment of pain |
WO2015119906A1 (en) | 2014-02-05 | 2015-08-13 | Amgen Inc. | Drug delivery system with electromagnetic field generator |
CN106029096A (zh) | 2014-02-14 | 2016-10-12 | 瑞泽恩制药公司 | 用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法 |
GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
AU2015256082C1 (en) | 2014-05-07 | 2020-09-10 | Amgen Inc. | Autoinjector with shock reducing elements |
AU2015259465A1 (en) | 2014-05-13 | 2016-11-17 | Bioatla Llc | Conditionally active biological proteins |
CN112237662B (zh) | 2014-06-03 | 2022-10-21 | 安姆根有限公司 | 药物递送系统和使用方法 |
WO2015200438A1 (en) * | 2014-06-24 | 2015-12-30 | Eleven Biotherapeutics, Inc. | High affinity antibodies against pcsk9 |
DE202015009007U1 (de) | 2014-07-15 | 2016-08-19 | Kymab Limited | Targeting von humaner PCSK9 zur Cholesterinbehandlung |
US9150660B1 (en) | 2014-07-15 | 2015-10-06 | Kymab Limited | Precision Medicine by targeting human NAV1.8 variants for treatment of pain |
EP2975059A1 (en) | 2014-07-15 | 2016-01-20 | Kymab Limited | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
US9139648B1 (en) | 2014-07-15 | 2015-09-22 | Kymab Limited | Precision medicine by targeting human NAV1.9 variants for treatment of pain |
EP4328245A3 (en) | 2014-07-15 | 2024-06-05 | Kymab Ltd. | Antibodies for use in treating conditions related to specific pcsk9 variants in specific patients populations |
MX2017000628A (es) * | 2014-07-16 | 2017-04-27 | Sanofi Biotechnology | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. |
KR20170029613A (ko) | 2014-07-16 | 2017-03-15 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
AR101262A1 (es) | 2014-07-26 | 2016-12-07 | Regeneron Pharma | Plataforma de purificación para anticuerpos biespecíficos |
US20170224816A1 (en) | 2014-08-06 | 2017-08-10 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
WO2016020799A1 (en) | 2014-08-06 | 2016-02-11 | Rinat Neuroscience Corp. | Methods for reducing ldl-cholesterol |
WO2016023916A1 (en) | 2014-08-12 | 2016-02-18 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
US11554181B2 (en) | 2014-09-05 | 2023-01-17 | The University Of North Carolina At Charlotte | Tumor specific antibody conjugates and uses therefor |
EP3194441A1 (en) | 2014-09-16 | 2017-07-26 | Regeneron Pharmaceuticals, Inc. | Anti-glucagon antibodies and uses thereof |
WO2016046684A1 (en) | 2014-09-23 | 2016-03-31 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
AU2015332557B2 (en) | 2014-10-14 | 2020-05-14 | Amgen Inc. | Drug injection device with visual and audio indicators |
CN107206070B (zh) | 2014-10-23 | 2022-01-18 | 美国安进公司 | 降低药物制剂的粘度 |
WO2016071701A1 (en) | 2014-11-07 | 2016-05-12 | Kymab Limited | Treatment of disease using ligand binding to targets of interest |
ES2785311T3 (es) | 2014-12-19 | 2020-10-06 | Amgen Inc | Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario |
JP6716566B2 (ja) | 2014-12-19 | 2020-07-01 | アムジエン・インコーポレーテツド | 近接センサ付き薬物送達装置 |
SG11201700841QA (en) | 2014-12-19 | 2017-03-30 | Chugai Pharmaceutical Co Ltd | Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use |
CN107108729A (zh) | 2015-02-05 | 2017-08-29 | 中外制药株式会社 | 包含离子浓度依赖性的抗原结合结构域的抗体,fc区变体,il‑8‑结合抗体,及其应用 |
CN105461809B (zh) * | 2015-02-11 | 2018-10-12 | 康融东方(广东)医药有限公司 | Pcsk9抗体、其药物组合物及其用途 |
CA2976935C (en) | 2015-02-17 | 2020-03-10 | Amgen Inc. | Drug delivery device with vacuum assisted securement and/or feedback |
EA039310B1 (ru) * | 2015-02-26 | 2022-01-12 | Санофи Байотекнолоджи | Способы снижения сердечно-сосудистого риска |
ES2905870T3 (es) | 2015-02-27 | 2022-04-12 | Amgen Inc | Dispositivo de suministro de fármacos que tiene un mecanismo de protección de aguja con un umbral de resistencia ajustable al movimiento de la protección de aguja |
EP3271405A1 (en) | 2015-03-20 | 2018-01-24 | Aarhus Universitet | Inhibitors of pcsk9 for treatment of lipoprotein metabolism disorders |
WO2016187354A1 (en) | 2015-05-18 | 2016-11-24 | Agensys, Inc. | Antibodies that bind to axl proteins |
EP3297663A4 (en) | 2015-05-18 | 2018-12-19 | Agensys, Inc. | Antibodies that bind to axl proteins |
CN106084058B (zh) * | 2015-07-15 | 2019-08-27 | 北京天广实生物技术股份有限公司 | 抗人pcsk9单克隆抗体 |
TW202340452A (zh) | 2015-08-04 | 2023-10-16 | 美商再生元醫藥公司 | 補充牛磺酸之細胞培養基及用法 |
EP3337828A1 (en) | 2015-08-18 | 2018-06-27 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
WO2017039786A1 (en) | 2015-09-02 | 2017-03-09 | Amgen Inc. | Syringe assembly adapter for a syringe |
WO2017055966A1 (en) | 2015-10-01 | 2017-04-06 | Pfizer Inc. | Low viscosity antibody compositions |
CN106589127A (zh) * | 2015-10-16 | 2017-04-26 | 钜川生物医药 | 一种pcsk9抗体及其制备方法和应用 |
CN105348390B (zh) * | 2015-10-26 | 2018-08-28 | 北京智仁美博生物科技有限公司 | 抗人pcsk9单克隆抗体 |
CN106810609A (zh) * | 2015-11-27 | 2017-06-09 | 苏州君盟生物医药科技有限公司 | 抗pcsk9抗体及其应用 |
WO2017100501A1 (en) | 2015-12-09 | 2017-06-15 | Amgen Inc. | Auto-injector with signaling cap |
JP7141336B2 (ja) | 2015-12-25 | 2022-09-22 | 中外製薬株式会社 | 抗ミオスタチン抗体および使用方法 |
KR20180093068A (ko) * | 2015-12-31 | 2018-08-20 | 지앙수 헨그루이 메디슨 컴퍼니 리미티드 | Pcsk9 항체, 이의 항원-결합 단편 및 이의 의학적 적용 |
WO2017120178A1 (en) | 2016-01-06 | 2017-07-13 | Amgen Inc. | Auto-injector with signaling electronics |
AU2017219602C1 (en) * | 2016-02-17 | 2024-05-09 | Regeneron Pharmaceuticals, Inc. | Methods for treating or preventing atherosclerosis by administering an inhibitor of ANGPTL3 |
CN109069868B (zh) | 2016-03-03 | 2023-06-06 | 瑞泽恩制药公司 | 通过施用与angptl3抑制剂组合的pcsk9抑制剂治疗高脂血症患者的方法 |
EP3429663B1 (en) | 2016-03-15 | 2020-07-15 | Amgen Inc. | Reducing probability of glass breakage in drug delivery devices |
US11066464B2 (en) | 2016-03-21 | 2021-07-20 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
WO2017163049A1 (en) | 2016-03-21 | 2017-09-28 | Kymab Limited | Anti-malarial antibodies that bind circumsporozoite protein |
CN107266575B (zh) * | 2016-04-07 | 2021-12-24 | 天士力生物医药股份有限公司 | 前蛋白转化酶枯草溶菌素kexin 9型的结合蛋白及其应用 |
WO2017189089A1 (en) | 2016-04-29 | 2017-11-02 | Amgen Inc. | Drug delivery device with messaging label |
WO2017192287A1 (en) | 2016-05-02 | 2017-11-09 | Amgen Inc. | Syringe adapter and guide for filling an on-body injector |
MX2018013616A (es) | 2016-05-13 | 2019-02-21 | Amgen Inc | Montaje de cubierta protectora de vial. |
US11238150B2 (en) | 2016-05-16 | 2022-02-01 | Amgen Inc. | Data encryption in medical devices with limited computational capability |
WO2017209899A1 (en) | 2016-06-03 | 2017-12-07 | Amgen Inc. | Impact testing apparatuses and methods for drug delivery devices |
CN107474140B (zh) * | 2016-06-08 | 2022-06-03 | 常州博嘉生物医药科技有限公司 | Pcsk9特异性的结合蛋白mv072及其应用 |
US9567399B1 (en) | 2016-06-20 | 2017-02-14 | Kymab Limited | Antibodies and immunocytokines |
WO2018029474A2 (en) | 2016-08-09 | 2018-02-15 | Kymab Limited | Anti-icos antibodies |
WO2018004842A1 (en) | 2016-07-01 | 2018-01-04 | Amgen Inc. | Drug delivery device having minimized risk of component fracture upon impact events |
CN109641947B (zh) * | 2016-07-20 | 2023-04-14 | 犹他大学研究基金会 | Cd229 car t细胞及其使用方法 |
CA3026050A1 (en) | 2016-08-05 | 2018-02-08 | Chugai Seiyaku Kabushiki Kaisha | Composition for prophylaxis or treatment of il-8 related diseases |
RU2764548C2 (ru) | 2016-08-09 | 2022-01-18 | Кимаб Лимитед | Анти-icos антитела |
US20190328965A1 (en) | 2016-08-17 | 2019-10-31 | Amgen Inc. | Drug delivery device with placement detection |
EP3504328A1 (en) | 2016-08-24 | 2019-07-03 | Regeneron Pharmaceuticals, Inc. | Host cell protein modification |
US11111313B2 (en) | 2016-09-20 | 2021-09-07 | WuXi Biologics Ireland Limited | Anti-PCSK9 antibodies |
US20200165354A1 (en) * | 2016-09-20 | 2020-05-28 | WuXi Biologics Ireland Limited | Novel Anti-PCSK9 Antibodies |
JP7275027B2 (ja) | 2016-10-06 | 2023-05-17 | アムジェン インコーポレイテッド | 粘度低下タンパク質医薬製剤 |
US11667697B2 (en) | 2016-10-19 | 2023-06-06 | Vanderbilt University | Human orthopoxvirus antibodies and methods of use therefor |
EP3529278A1 (en) | 2016-10-20 | 2019-08-28 | Regeneron Pharmaceuticals, Inc. | Methods of lowering blood glucose levels |
EP3532127A1 (en) | 2016-10-25 | 2019-09-04 | Amgen Inc. | On-body injector |
WO2018083248A1 (en) | 2016-11-03 | 2018-05-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
JOP20190112A1 (ar) | 2016-11-14 | 2019-05-14 | Amgen Inc | علاجات مدمجة لتصلب الشرايين، شاملة مرض قلبي وعائي تصلبي |
CN108239150A (zh) | 2016-12-24 | 2018-07-03 | 信达生物制药(苏州)有限公司 | 抗pcsk9抗体及其用途 |
AU2018210301A1 (en) | 2017-01-17 | 2019-08-01 | Amgen Inc. | Injection devices and related methods of use and assembly |
CN107698680B (zh) * | 2017-01-22 | 2019-03-01 | 北京东方百泰生物科技有限公司 | 抗pcsk9单克隆抗体 |
CN108424457B (zh) * | 2017-02-13 | 2021-06-01 | 成都金洛克锶生物技术有限公司 | 针对pcsk9抗体与检测试剂盒的制备及其用途 |
MX2019009755A (es) | 2017-02-17 | 2019-10-07 | Amgen Inc | Mecanismo de insercion para dispositivo de suministro de farmacos. |
WO2018151890A1 (en) | 2017-02-17 | 2018-08-23 | Amgen Inc. | Drug delivery device with sterile fluid flowpath and related method of assembly |
EP3592403A1 (en) | 2017-03-06 | 2020-01-15 | Amgen Inc. | Drug delivery device with activation prevention feature |
IL268478B2 (en) | 2017-03-07 | 2023-10-01 | Amgen Inc | Inserting a needle using super pressure |
IL268386B2 (en) | 2017-03-09 | 2023-11-01 | Amgen Inc | Insertion mechanism for a drug delivery device |
EP4241807A3 (en) | 2017-03-28 | 2023-10-11 | Amgen Inc. | Plunger rod and syringe assembly system and method |
US9989519B1 (en) * | 2017-05-04 | 2018-06-05 | Clayton Pharmaceuticals, LLC | Method for determining in vitro bioequivalence of a sucralfate suspension sample to a sucralfate suspension reference listed drug (RLD) |
AU2018280054B2 (en) | 2017-06-08 | 2023-07-13 | Amgen Inc. | Syringe assembly for a drug delivery device and method of assembly |
AU2018282077B2 (en) | 2017-06-08 | 2023-11-23 | Amgen Inc. | Torque driven drug delivery device |
US20190031774A1 (en) | 2017-06-09 | 2019-01-31 | Sanofi Biotechnology | Methods for treating hyperlipidemia in diabetic patients by administering a pcsk9 inhibitor |
TW202310872A (zh) * | 2017-06-09 | 2023-03-16 | 法商賽諾菲生物技術公司 | 藉由投予pcsk9抑制劑治療糖尿病患者高血脂症之方法 |
GB201709808D0 (en) | 2017-06-20 | 2017-08-02 | Kymab Ltd | Antibodies |
US11541183B2 (en) | 2017-06-22 | 2023-01-03 | Amgen Inc. | Device activation impact/shock reduction |
JP7475860B2 (ja) | 2017-06-23 | 2024-04-30 | アムジエン・インコーポレーテツド | スイッチアセンブリにより起動されるキャップを含む電子薬物送達デバイス |
CN110914293A (zh) | 2017-07-06 | 2020-03-24 | 里珍纳龙药品有限公司 | 用于制备糖蛋白的细胞培养工艺 |
ES2972207T3 (es) | 2017-07-14 | 2024-06-11 | Amgen Inc | Sistema de inserción-retracción de agujas con sistema de resorte de torsión doble |
MA49626A (fr) | 2017-07-21 | 2020-05-27 | Amgen Inc | Élément d'étanchéité perméable aux gaz pour récipient à médicament et procédés d'assemblage |
EP4085942A1 (en) | 2017-07-25 | 2022-11-09 | Amgen Inc. | Drug delivery device with gear module and related method of assembly |
EP3658206A1 (en) | 2017-07-25 | 2020-06-03 | Amgen Inc. | Drug delivery device with container access system and related method of assembly |
EP3664863A2 (en) | 2017-08-09 | 2020-06-17 | Amgen Inc. | Hydraulic-pneumatic pressurized chamber drug delivery system |
EP3668567A1 (en) | 2017-08-18 | 2020-06-24 | Amgen Inc. | Wearable injector with sterile adhesive patch |
US11103636B2 (en) | 2017-08-22 | 2021-08-31 | Amgen Inc. | Needle insertion mechanism for drug delivery device |
WO2019070472A1 (en) | 2017-10-04 | 2019-04-11 | Amgen Inc. | FLOW ADAPTER FOR MEDICATION DELIVERY DEVICE |
IL272636B1 (en) | 2017-10-06 | 2024-06-01 | Amgen Inc | Drug delivery device with combination assembly and related assembly method |
WO2019074579A1 (en) | 2017-10-09 | 2019-04-18 | Amgen Inc. | DRUG DELIVERY DEVICE COMPRISING A DRIVE ASSEMBLY AND ASSEMBLY METHOD THEREOF |
EP3703778A1 (en) | 2017-11-03 | 2020-09-09 | Amgen Inc. | System and approaches for sterilizing a drug delivery device |
WO2019089178A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Drug delivery device with placement and flow sensing |
WO2019090303A1 (en) | 2017-11-06 | 2019-05-09 | Amgen Inc. | Fill-finish assemblies and related methods |
SG11202002966QA (en) | 2017-11-10 | 2020-05-28 | Amgen Inc | Plungers for drug delivery devices |
SG11202002772VA (en) | 2017-11-16 | 2020-04-29 | Amgen Inc | Autoinjector with stall and end point detection |
IL273638B1 (en) | 2017-11-16 | 2024-06-01 | Amgen Inc | Door lock mechanism for drug delivery device |
GB201721338D0 (en) | 2017-12-19 | 2018-01-31 | Kymab Ltd | Anti-icos Antibodies |
US11629189B2 (en) | 2017-12-19 | 2023-04-18 | Kymab Limited | Bispecific antibody for ICOS and PD-L1 |
CN111479618B (zh) | 2017-12-22 | 2022-08-02 | 瑞泽恩制药公司 | 用于表征药物产品杂质的系统和方法 |
US20200362055A1 (en) * | 2018-01-31 | 2020-11-19 | The Wistar Institute Of Anatomy And Biology | Nucleic acid monoclonal antibodies targeting pcsk9 and methods of use |
SG11202005235WA (en) | 2018-01-31 | 2020-07-29 | Regeneron Pharma | System and method for characterizing size and charge variant drug product impurities |
TW202311746A (zh) | 2018-02-02 | 2023-03-16 | 美商再生元醫藥公司 | 用於表徵蛋白質二聚合之系統及方法 |
US11957745B2 (en) | 2018-02-22 | 2024-04-16 | Vanderbilt University | Human Japanese Encephalitis Virus antibodies and methods of use therefor |
CN111771000A (zh) | 2018-02-28 | 2020-10-13 | 瑞泽恩制药公司 | 用于鉴定病毒污染物的系统和方法 |
WO2019173530A1 (en) | 2018-03-06 | 2019-09-12 | Sanofi Biotechnology | Use of pcsk9 inhibitor for reducing cardiovascular risk |
WO2019182901A1 (en) | 2018-03-19 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Microchip capillary electrophoresis assays and reagents |
TW202016125A (zh) | 2018-05-10 | 2020-05-01 | 美商再生元醫藥公司 | 用於定量及調節蛋白質黏度之系統與方法 |
US10835685B2 (en) | 2018-05-30 | 2020-11-17 | Amgen Inc. | Thermal spring release mechanism for a drug delivery device |
US11083840B2 (en) | 2018-06-01 | 2021-08-10 | Amgen Inc. | Modular fluid path assemblies for drug delivery devices |
US11530274B2 (en) | 2018-07-02 | 2022-12-20 | Amgen Inc. | Anti-STEAP1 antigen-binding protein |
MX2021000749A (es) | 2018-07-24 | 2021-03-29 | Amgen Inc | Dispositivos de suministro para administrar farmacos. |
US12042645B2 (en) | 2018-07-24 | 2024-07-23 | Amgen Inc. | Delivery devices for administering drugs |
WO2020023220A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with tacky skin attachment portion and related method of preparation |
WO2020023336A1 (en) | 2018-07-24 | 2020-01-30 | Amgen Inc. | Hybrid drug delivery devices with grip portion |
WO2020028009A1 (en) | 2018-07-31 | 2020-02-06 | Amgen Inc. | Fluid path assembly for a drug delivery device |
SG11202011970TA (en) | 2018-08-27 | 2020-12-30 | Regeneron Pharma | Use of raman spectroscopy in downstream purification |
EP3775926A1 (en) | 2018-08-30 | 2021-02-17 | Regeneron Pharmaceuticals, Inc. | Methods for characterizing protein complexes |
CN110872353B (zh) * | 2018-09-03 | 2021-05-04 | 深圳华大基因科技有限公司 | 特异性结合pcsk9抗原的纳米抗体及其制备方法和应用 |
US20210346601A1 (en) | 2018-09-24 | 2021-11-11 | Amgen Inc. | Interventional dosing systems and methods |
CA3110371A1 (en) | 2018-09-28 | 2020-04-02 | Amgen Inc. | Muscle wire escapement activation assembly for a drug delivery device |
EP3860685A1 (en) | 2018-10-02 | 2021-08-11 | Amgen Inc. | Injection systems for drug delivery with internal force transmission |
EP3860686A1 (en) | 2018-10-05 | 2021-08-11 | Amgen Inc. | Drug delivery device having dose indicator |
CA3109988A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Platform assembly process for drug delivery device |
MA53912A (fr) | 2018-10-15 | 2022-01-19 | Amgen Inc | Dispositif d'administration de médicament comprenant un mécanisme d'amortissement |
JP2022513406A (ja) * | 2018-10-31 | 2022-02-07 | デリニア インコーポレイテッド | 多価制御性t細胞調節因子 |
CN111110841A (zh) * | 2018-10-31 | 2020-05-08 | 上海君实生物医药科技股份有限公司 | 含有抗pcsk9抗体的稳定制剂 |
US11213620B2 (en) | 2018-11-01 | 2022-01-04 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
TWI831847B (zh) | 2018-11-01 | 2024-02-11 | 美商安進公司 | 部分針頭縮回之藥物遞送裝置及其操作方法 |
CA3113076A1 (en) | 2018-11-01 | 2020-05-07 | Amgen Inc. | Drug delivery devices with partial drug delivery member retraction |
JP2022517720A (ja) | 2019-01-16 | 2022-03-10 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | ジスルフィド結合を特徴付けるための方法 |
CN109734813B (zh) * | 2019-01-28 | 2022-06-17 | 广东昭泰体内生物医药科技有限公司 | 一种嵌合抗原受体及其应用 |
MX2021012557A (es) | 2019-04-24 | 2021-11-12 | Amgen Inc | Conjuntos y metodos de verificacion de esterilizacion de jeringuillas. |
CN113785203A (zh) | 2019-05-13 | 2021-12-10 | 里珍纳龙药品有限公司 | 改进的竞争性配体结合测定 |
US20210002724A1 (en) | 2019-05-17 | 2021-01-07 | Regeneron Pharmaceuticals, Inc. | Genome-Based Methods For Reducing Cardiovascular Risk |
MX2022002149A (es) | 2019-08-23 | 2022-03-17 | Amgen Inc | Dispositivo de suministro de farmacos con componentes de acoplamiento de capuchon de aguja configurable y metodos relacionados. |
WO2021058597A1 (en) | 2019-09-24 | 2021-04-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods of determining whether a subject is at risk of developing arterial plaques |
WO2021061790A1 (en) | 2019-09-24 | 2021-04-01 | Regeneron Pharmaceuticals, Inc. | Systems and methods for chromatography use and regeneration |
US11730793B2 (en) | 2019-11-25 | 2023-08-22 | Regeneron Pharmaceuticals, Inc. | Sustained release formulations using non-aqueous emulsions |
AU2020402044A1 (en) | 2019-12-10 | 2022-07-28 | Regeneron Pharmaceuticals, Inc. | Use of a PCSK9 inhibitor to treat homozygous familial hypercholesterolemia |
CN115398236B (zh) | 2020-01-21 | 2024-06-11 | 瑞泽恩制药公司 | 用于糖基化的蛋白质的电泳的去糖基化方法 |
WO2022031882A1 (en) * | 2020-08-06 | 2022-02-10 | Stelexis Therapeutics, Llc | Il-8 antibodies and methods of use thereof |
WO2022047108A1 (en) | 2020-08-31 | 2022-03-03 | Regeneron Pharmaceuticals, Inc. | Asparagine feed strategies to improve cell culture performance and mitigate asparagine sequence variants |
CA3191141A1 (en) | 2020-11-25 | 2022-06-02 | Hunter Chen | Sustained release formulations using non-aqueous membrane emulsification |
MX2023007225A (es) | 2020-12-17 | 2023-06-27 | Regeneron Pharma | Fabricacion de microgeles encapsuladores de proteina. |
KR20230134117A (ko) | 2021-01-20 | 2023-09-20 | 리제너론 파마슈티칼스 인코포레이티드 | 세포 배양물에서 단백질 역가를 개선시키는 방법 |
CA3207883A1 (en) | 2021-03-03 | 2022-09-09 | Xiaobin Xu | Systems and methods for quantifying and modifying protein viscosity |
JP2024519407A (ja) | 2021-03-26 | 2024-05-13 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 混合プロトコルを作成するための方法およびシステム |
TW202313682A (zh) | 2021-05-18 | 2023-04-01 | 英商凱麥博有限公司 | 抗icos抗體之用途 |
US20240208680A1 (en) | 2021-05-21 | 2024-06-27 | Amgen Inc. | Method of optimizing a filling recipe for a drug container |
MX2023014246A (es) | 2021-06-01 | 2024-01-17 | Regeneron Pharma | Ensayos y reactivos de microchips de electroforesis capilar. |
GB202107994D0 (en) | 2021-06-04 | 2021-07-21 | Kymab Ltd | Treatment of cancer |
EP4367134A1 (en) | 2021-07-05 | 2024-05-15 | Regeneron Pharmaceuticals, Inc. | Utilization of antibodies to shape antibody responses to an antigen |
US20230077710A1 (en) | 2021-09-08 | 2023-03-16 | Regeneron Pharmaceuticals, Inc. | HIGH-THROUGHPUT AND MASS-SPECTROMETRY-BASED METHOD FOR QUANTITATING ANTIBODIES AND OTHER Fc-CONTAINING PROTEINS |
CA3232463A1 (en) | 2021-09-20 | 2023-03-23 | Philip Mellors | Methods of controlling antibody heterogeneity |
IL311245A (en) | 2021-10-07 | 2024-05-01 | Regeneron Pharma | Systems and methods for pH modeling and control |
IL311248A (en) | 2021-10-07 | 2024-05-01 | Regeneron Pharma | PH meter calibration and repair |
KR20240097864A (ko) | 2021-10-26 | 2024-06-27 | 리제너론 파마슈티칼스 인코포레이티드 | 상이한 온도에서 실험실 용수를 생성하고 실험실 용수를 분배하는 시스템 및 방법 |
WO2023177836A1 (en) | 2022-03-18 | 2023-09-21 | Regeneron Pharmaceuticals, Inc. | Methods and systems for analyzing polypeptide variants |
WO2023222854A1 (en) | 2022-05-18 | 2023-11-23 | Kymab Limited | Uses of anti-icos antibodies |
WO2024040020A1 (en) | 2022-08-15 | 2024-02-22 | Absci Corporation | Quantitative affinity activity specific cell enrichment |
WO2024130165A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Angptl3 inhibitors for triglyceride reduction in multifactorial chylomicronemia syndrome |
WO2024130048A1 (en) | 2022-12-16 | 2024-06-20 | Regeneron Pharmaceuticals, Inc. | Methods and systems for assessing chromatographic column integrity |
Family Cites Families (114)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
EP0463151B1 (en) | 1990-01-12 | 1996-06-12 | Cell Genesys, Inc. | Generation of xenogeneic antibodies |
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
WO1993000807A1 (en) | 1991-07-03 | 1993-01-21 | Cryolife, Inc. | Method for stabilization of biomaterials |
AU670793B2 (en) | 1992-04-30 | 1996-08-01 | Alpha Therapeutic Corporation | Improved solubilization and stabilization of factor VIII complex |
US6177401B1 (en) | 1992-11-13 | 2001-01-23 | Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften | Use of organic compounds for the inhibition of Flk-1 mediated vasculogenesis and angiogenesis |
GB9410534D0 (en) | 1994-05-26 | 1994-07-13 | Lynxvale Ltd | Improvements in or relating to growth factor inhibitors |
US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
US6685940B2 (en) | 1995-07-27 | 2004-02-03 | Genentech, Inc. | Protein formulation |
JPH09154588A (ja) | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Vegf結合性ポリペプチド |
AU2548097A (en) | 1996-03-26 | 1997-10-17 | Eli Lilly And Company | Formulations of ob protein |
US6100071A (en) | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
EP0852951A1 (de) | 1996-11-19 | 1998-07-15 | Roche Diagnostics GmbH | Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern |
US7312196B2 (en) | 1997-01-08 | 2007-12-25 | Amylin Pharmaceuticals, Inc. | Formulations for amylin agonist peptides |
US20070224663A1 (en) | 1997-03-07 | 2007-09-27 | Human Genome Sciences, Inc. | Human Secreted Proteins |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
CA2317411C (en) | 1998-01-30 | 2005-06-28 | Scios Inc. | Controlled release delivery of peptide or protein |
US7001892B1 (en) | 1999-06-11 | 2006-02-21 | Purdue Research Foundation | Pharmaceutical materials and methods for their preparation and use |
EP1067182A3 (en) | 1999-07-08 | 2001-11-21 | Helix Research Institute | Secretory protein or membrane protein |
US7129338B1 (en) | 1999-07-08 | 2006-10-31 | Research Association For Biotechnology | Secretory protein or membrane protein |
US7029895B2 (en) | 1999-09-27 | 2006-04-18 | Millennium Pharmaceuticals, Inc. | 27411, a novel human PGP synthase |
CA2399727A1 (en) | 2000-02-07 | 2001-08-09 | Millennium Pharmaceuticals, Inc. | Narc-1, subtilase-like homologs |
US6659982B2 (en) | 2000-05-08 | 2003-12-09 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
US6629949B1 (en) | 2000-05-08 | 2003-10-07 | Sterling Medivations, Inc. | Micro infusion drug delivery device |
MXPA03002046A (es) | 2000-09-08 | 2003-07-24 | Massachusetts Inst Technology | Composiciones analogos de factor estimulador de colonias de granulocitos y metodos para su elaboracion. |
ES2332402T5 (es) | 2000-10-12 | 2018-05-14 | Genentech, Inc. | Formulaciones de proteína concentradas de viscosidad reducida |
US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
US20030133939A1 (en) | 2001-01-17 | 2003-07-17 | Genecraft, Inc. | Binding domain-immunoglobulin fusion proteins |
US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
CA2454587C (en) | 2001-07-25 | 2012-11-13 | Protein Design Labs, Inc. | Stable lyophilized pharmaceutical formulation of igg antibodies |
US20040101920A1 (en) | 2002-11-01 | 2004-05-27 | Czeslaw Radziejewski | Modification assisted profiling (MAP) methodology |
AU2003293543A1 (en) | 2002-12-13 | 2004-07-09 | Abgenix, Inc. | System and method for stabilizing antibodies with histidine |
CN1798575A (zh) | 2003-04-04 | 2006-07-05 | 健泰科生物技术公司 | 高浓度抗体和蛋白制剂 |
EP1471152A1 (en) | 2003-04-25 | 2004-10-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Mutations in the human PCSK9 gene associated to hypercholesterolemia |
US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
US20060147945A1 (en) | 2005-01-06 | 2006-07-06 | Edmonds Brian T | Novel secreted proteins and their uses |
ES2366973T3 (es) | 2006-05-05 | 2011-10-27 | Isis Pharmaceuticals, Inc. | Compuestos y procedimiento para modular la expresión génica. |
ES2386578T3 (es) | 2006-05-05 | 2012-08-23 | Isis Pharmaceuticals, Inc. | Compuestos y procedimientos para modular la expresión de PCSK9 |
DK2374818T3 (da) | 2006-06-02 | 2013-01-21 | Regeneron Pharma | Højaffinitetsantistoffer mod human IL-6-receptor |
KR101406811B1 (ko) | 2006-06-16 | 2014-06-12 | 리제너론 파마슈티칼스 인코포레이티드 | 유리체내 투여에 적당한 vegf 길항제 제형 |
US7572618B2 (en) | 2006-06-30 | 2009-08-11 | Bristol-Myers Squibb Company | Polynucleotides encoding novel PCSK9 variants |
US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
EP2083860A4 (en) | 2006-11-07 | 2010-05-26 | Merck Sharp & Dohme | PCSK9 ANTAGONISTS |
JP5588175B2 (ja) | 2006-11-07 | 2014-09-10 | メルク・シャープ・アンド・ドーム・コーポレーション | Pcsk9のアンタゴニスト |
WO2008133647A2 (en) | 2006-11-07 | 2008-11-06 | Merck & Co., Inc. | Antagonists of pcsk9 |
EP2083859A4 (en) | 2006-11-07 | 2010-11-24 | Merck Sharp & Dohme | ANTAGONISTS OF PCSK9 |
EP2453016A1 (en) | 2006-11-27 | 2012-05-16 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
US8093222B2 (en) | 2006-11-27 | 2012-01-10 | Isis Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia |
CN101679527A (zh) | 2007-04-13 | 2010-03-24 | 诺瓦提斯公司 | 用于调节前蛋白转化酶枯草杆菌蛋白酶/kexin9型(pcsk9)的分子和方法 |
CN101687927B (zh) | 2007-05-15 | 2013-10-30 | 霍夫曼-拉罗奇有限公司 | 针对g蛋白偶联的受体(gpcr)的抗体 |
JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
WO2009042765A1 (en) | 2007-09-25 | 2009-04-02 | The Regents Of The University Of California | Methods of modulating prokineticin 2 for treatment of stress response and anxiety-related disorders |
JP2011501952A (ja) * | 2007-10-26 | 2011-01-20 | シェーリング コーポレイション | 脂質障害およびコレステロール障害を治療するための抗pcsk9および方法 |
AR070316A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9) |
AR070315A1 (es) | 2008-02-07 | 2010-03-31 | Merck & Co Inc | Anticuerpos 1b20 antagonistas de pcsk9 |
ES2563483T3 (es) | 2008-04-11 | 2016-03-15 | Chugai Seiyaku Kabushiki Kaisha | Molécula de unión a antígeno capaz de unirse repetidamente a dos o más moléculas de antígeno |
TWI445716B (zh) | 2008-09-12 | 2014-07-21 | Rinat Neuroscience Corp | Pcsk9拮抗劑類 |
SI2331090T1 (en) | 2008-09-19 | 2018-04-30 | Pfizer Inc. | Stable liquid antibody formulation |
TWI440469B (zh) | 2008-09-26 | 2014-06-11 | Chugai Pharmaceutical Co Ltd | Improved antibody molecules |
WO2010068526A1 (en) | 2008-12-12 | 2010-06-17 | Merck Sharp & Dohme Corp. | Pcsk9 immunoassay |
US8357371B2 (en) | 2008-12-15 | 2013-01-22 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to PCSK9 |
JO3672B1 (ar) | 2008-12-15 | 2020-08-27 | Regeneron Pharma | أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9). |
US20130064834A1 (en) | 2008-12-15 | 2013-03-14 | Regeneron Pharmaceuticals, Inc. | Methods for treating hypercholesterolemia using antibodies to pcsk9 |
AU2010221156A1 (en) | 2009-03-06 | 2011-09-22 | Genentech, Inc. | Antibody formulation |
EP2442798A4 (en) | 2009-06-18 | 2013-03-13 | Wyeth Llc | LYOPHILIZED FORMULATIONS FOR SMALL-SCALE MODULAR IMMUNOPHARMACEUTICAL AGENTS |
WO2011028938A1 (en) | 2009-09-02 | 2011-03-10 | Alnylam Pharmaceuticals, Inc. | Methods for lowering serum cholestrol in a subject using inhibition of pcsk9 |
WO2011037791A1 (en) | 2009-09-25 | 2011-03-31 | Merck Sharp & Dohme Corp. | Antagonists of pcsk9 |
WO2011039578A1 (en) | 2009-10-02 | 2011-04-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Combination of spla2 activity and lp(a) cardiovascular risk factors for the diagnosis/prognosis of a cardiovascular disease/event |
AU2010313381A1 (en) | 2009-10-30 | 2012-04-12 | Merck Sharp & Dohme Corp. | AX1 and AX189 PCSK9 antagonists and variants |
CN102639150A (zh) | 2009-10-30 | 2012-08-15 | 默沙东公司 | Ax213和ax132 pcsk9拮抗剂和变体 |
PT3721904T (pt) | 2009-11-20 | 2021-11-15 | Biocon Ltd | Formulações de anticorpo t1h |
AR079336A1 (es) | 2009-12-11 | 2012-01-18 | Irm Llc | Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9) |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
SG183867A1 (en) | 2010-03-11 | 2012-10-30 | Rinat Neuroscience Corp | ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING |
GB201005005D0 (en) | 2010-03-25 | 2010-05-12 | Angeletti P Ist Richerche Bio | New vaccine |
WO2012044999A2 (en) * | 2010-10-01 | 2012-04-05 | Ludwig Institute For Cancer Research Ltd. | Reversible protein multimers, methods for their production and use |
EP3733711A1 (en) | 2010-10-06 | 2020-11-04 | Regeneron Pharmaceuticals, Inc. | Stabilized formulations containing anti-interleukin-4 receptor (il-4r) antibodies |
WO2012054438A1 (en) | 2010-10-22 | 2012-04-26 | Schering Corporation | Anti-pcsk9 |
CA2817015A1 (en) | 2010-11-09 | 2012-05-18 | Altimab Therapeutics, Inc. | Protein complexes for antigen binding and methods of use |
JO3756B1 (ar) * | 2010-11-23 | 2021-01-31 | Regeneron Pharma | اجسام مضادة بشرية لمستقبلات الجلوكاجون |
US8771696B2 (en) * | 2010-11-23 | 2014-07-08 | Regeneron Pharmaceuticals, Inc. | Method of reducing the severity of stress hyperglycemia with human antibodies to the glucagon receptor |
SG191219A1 (en) | 2010-12-22 | 2013-07-31 | Genentech Inc | Anti-pcsk9 antibodies and methods of use |
AR084938A1 (es) | 2011-01-28 | 2013-07-10 | Sanofi Sa | Anticuerpos humanos contra la proproteina convertasa subtilisina/kexina tipo 9 (anti pcsk9) para usar en metodos para tratar grupos de pacientes |
MX2013009258A (es) | 2011-02-11 | 2013-10-17 | Novartis Ag | Antagonistas de pcsk9. |
AR088782A1 (es) | 2011-04-29 | 2014-07-10 | Sanofi Sa | Sistemas de ensayo y metodos para identificar y caracterizar farmacos hipolipemiantes |
US20140004122A1 (en) | 2011-05-10 | 2014-01-02 | Amgen Inc. | Methods for treating or preventing cholesterol related disorders |
JOP20200043A1 (ar) | 2011-05-10 | 2017-06-16 | Amgen Inc | طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول |
US20140161821A1 (en) | 2011-07-14 | 2014-06-12 | Pfizer Inc. | Treatment with anti-pcsk9 antibodies |
AR087305A1 (es) | 2011-07-28 | 2014-03-12 | Regeneron Pharma | Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit |
AU2012308797B2 (en) | 2011-09-16 | 2017-06-01 | Regeneron Pharmaceuticals, Inc. | Methods for reducing lipoprotein(a) levels by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PSCK9) |
AR087715A1 (es) | 2011-09-16 | 2014-04-09 | Lilly Co Eli | Anticuerpos anti pcsk9 y usos de los mismos |
WO2013158984A1 (en) | 2012-04-19 | 2013-10-24 | Acetylon Pharmaceuticals, Inc. | Biomarkers to identify patients that will respond to treatment and treating such patients |
EA039663B1 (ru) | 2012-05-03 | 2022-02-24 | Амген Инк. | Применение антитела против pcsk9 для снижения сывороточного холестерина лпнп и лечения связанных с холестерином расстройств |
US9255154B2 (en) | 2012-05-08 | 2016-02-09 | Alderbio Holdings, Llc | Anti-PCSK9 antibodies and use thereof |
CA2874244A1 (en) | 2012-05-25 | 2013-11-28 | Catabasis Pharmaceuticals, Inc. | Methods of lowering proprotein convertase subtilisin/kexin type 9 (pcsk9) |
US9540449B2 (en) * | 2012-08-13 | 2017-01-10 | Regeneron Pharmaceuticals, Inc. | Anti-PCSK9 antibodies with pH-dependent binding characteristics |
EP2703008A1 (en) | 2012-08-31 | 2014-03-05 | Sanofi | Human antibodies to PCSK9 for use in methods of treating particular groups of subjects |
EP2703009A1 (en) | 2012-08-31 | 2014-03-05 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
EP2706070A1 (en) | 2012-09-06 | 2014-03-12 | Sanofi | Combination treatments involving antibodies to human PCSK9 |
TWI682780B (zh) | 2013-05-30 | 2020-01-21 | 美商再生元醫藥公司 | 醫藥組成物用於製造治療與pcsk9功能獲得性突變有關之體染色體顯性高膽固醇血症的藥物之用途 |
US10111953B2 (en) | 2013-05-30 | 2018-10-30 | Regeneron Pharmaceuticals, Inc. | Methods for reducing remnant cholesterol and other lipoprotein fractions by administering an inhibitor of proprotein convertase subtilisin kexin-9 (PCSK9) |
KR20160024906A (ko) | 2013-06-07 | 2016-03-07 | 사노피 바이오테크놀로지 | Pcsk9의 억제제를 투여함에 의한 죽상경화증의 억제 방법 |
JP6846931B2 (ja) | 2013-10-11 | 2021-03-24 | サノフィ・バイオテクノロジー | 高脂血症を処置するためのpcsk9阻害剤の使用 |
EP3882273A1 (en) | 2013-11-12 | 2021-09-22 | Sanofi Biotechnology | Dosing regimens for use with pcsk9 inhibitors |
US8945560B1 (en) | 2014-07-15 | 2015-02-03 | Kymab Limited | Method of treating rheumatoid arthritis using antibody to IL6R |
US8883157B1 (en) * | 2013-12-17 | 2014-11-11 | Kymab Limited | Targeting rare human PCSK9 variants for cholesterol treatment |
US9034332B1 (en) * | 2014-07-15 | 2015-05-19 | Kymab Limited | Precision medicine by targeting rare human PCSK9 variants for cholesterol treatment |
CN106029096A (zh) | 2014-02-14 | 2016-10-12 | 瑞泽恩制药公司 | 用于治疗具有未被中等剂量他汀疗法充分控制的高胆固醇血症的患者的方法 |
US20150283236A1 (en) | 2014-03-17 | 2015-10-08 | Marie Baccara-Dinet | Methods for treating subjects with primary hypercholesterolemia that is not adequately controlled |
MX2017000628A (es) | 2014-07-16 | 2017-04-27 | Sanofi Biotechnology | Metodos para tratar pacientes de alto riesgo cardiovascular con hipercolesterolemia. |
KR20170029613A (ko) | 2014-07-16 | 2017-03-15 | 사노피 바이오테크놀로지 | 이형접합성 가족성 고콜레스테롤혈증(heFH) 환자의 치료방법 |
EA039310B1 (ru) | 2015-02-26 | 2022-01-12 | Санофи Байотекнолоджи | Способы снижения сердечно-сосудистого риска |
EP3337828A1 (en) | 2015-08-18 | 2018-06-27 | Regeneron Pharmaceuticals, Inc. | Anti-pcsk9 inhibitory antibodies for treating patients with hyperlipidemia undergoing lipoprotein apheresis |
US10933134B2 (en) | 2017-03-16 | 2021-03-02 | Memorial Sloan Kettering Cancer Center | Combination therapies for treatment of cancer |
-
2009
- 2009-12-14 JO JOP/2009/0481A patent/JO3672B1/ar active
- 2009-12-15 BR BRPI0922885-3A patent/BRPI0922885B1/pt active IP Right Grant
- 2009-12-15 AR ARP090104880A patent/AR077724A1/es active IP Right Grant
- 2009-12-15 HU HUE09793408A patent/HUE032681T2/en unknown
- 2009-12-15 HU HUE16200305A patent/HUE056244T2/hu unknown
- 2009-12-15 RU RU2011129316A patent/RU2552169C3/ru active Protection Beyond IP Right Term
- 2009-12-15 HR HRP20170488TT patent/HRP20170488T4/hr unknown
- 2009-12-15 EP EP09793408.7A patent/EP2358756B2/en active Active
- 2009-12-15 US US12/637,942 patent/US8062640B2/en active Active
- 2009-12-15 ES ES09793408T patent/ES2613489T5/es active Active
- 2009-12-15 UA UAA201108829A patent/UA105650C2/uk unknown
- 2009-12-15 LT LTEP09793408.7T patent/LT2358756T/lt unknown
- 2009-12-15 KR KR1020117013676A patent/KR101504494B1/ko active IP Right Grant
- 2009-12-15 SI SI200931637T patent/SI2358756T2/sl unknown
- 2009-12-15 LT LTEP16200305.7T patent/LT3156422T/lt unknown
- 2009-12-15 AU AU2009333326A patent/AU2009333326B9/en active Active
- 2009-12-15 PT PT97934087T patent/PT2358756T/pt unknown
- 2009-12-15 PL PL09793408.7T patent/PL2358756T5/pl unknown
- 2009-12-15 NZ NZ601923A patent/NZ601923A/xx unknown
- 2009-12-15 PA PA20098854201A patent/PA8854201A1/es unknown
- 2009-12-15 ME MEP-2011-111A patent/ME01327B/me unknown
- 2009-12-15 MX MX2014004581A patent/MX341041B/es unknown
- 2009-12-15 RS RS20211437A patent/RS62580B1/sr unknown
- 2009-12-15 ES ES16200305T patent/ES2898661T3/es active Active
- 2009-12-15 RU RU2015109166A patent/RU2697773C2/ru active
- 2009-12-15 WO PCT/US2009/068013 patent/WO2010077854A1/en active Application Filing
- 2009-12-15 NZ NZ593155A patent/NZ593155A/xx unknown
- 2009-12-15 HR HRP20211688TT patent/HRP20211688T1/hr unknown
- 2009-12-15 EP EP16200305.7A patent/EP3156422B1/en active Active
- 2009-12-15 DK DK09793408.7T patent/DK2358756T4/da active
- 2009-12-15 PT PT162003057T patent/PT3156422T/pt unknown
- 2009-12-15 CN CN201410749251.XA patent/CN104447997A/zh active Pending
- 2009-12-15 TW TW098142896A patent/TWI465249B/zh active
- 2009-12-15 UY UY0001032329A patent/UY32329A/es not_active Application Discontinuation
- 2009-12-15 PL PL16200305T patent/PL3156422T3/pl unknown
- 2009-12-15 DK DK16200305.7T patent/DK3156422T3/da active
- 2009-12-15 PE PE2011001214A patent/PE20120014A1/es active IP Right Grant
- 2009-12-15 KR KR1020157001056A patent/KR101699707B1/ko active IP Right Grant
- 2009-12-15 CN CN200980150206.XA patent/CN102245641B/zh active Active
- 2009-12-15 MX MX2011006197A patent/MX2011006197A/es active IP Right Grant
- 2009-12-15 SI SI200932149T patent/SI3156422T1/sl unknown
- 2009-12-15 EP EP21185555.6A patent/EP3943510A3/en active Pending
- 2009-12-15 JP JP2011540965A patent/JP5318965B2/ja active Active
- 2009-12-15 RS RS20170255A patent/RS55771B2/sr unknown
- 2009-12-15 CA CA2747123A patent/CA2747123C/en active Active
- 2009-12-15 ME MEP-2017-70A patent/ME02760B/me unknown
-
2010
- 2010-11-19 US US12/949,846 patent/US8501184B2/en active Active
-
2011
- 2011-05-22 IL IL213050A patent/IL213050A/en active IP Right Grant
- 2011-05-23 ZA ZA2011/03762A patent/ZA201103762B/en unknown
- 2011-06-02 CR CR20110296A patent/CR20110296A/es unknown
- 2011-06-06 NI NI201100111A patent/NI201100111A/es unknown
- 2011-06-13 TN TN2011000300A patent/TN2011000300A1/fr unknown
- 2011-06-13 DO DO2011000184A patent/DOP2011000184A/es unknown
- 2011-06-14 HN HN2011001659A patent/HN2011001659A/es unknown
- 2011-06-14 CO CO11073672A patent/CO6571847A2/es active IP Right Grant
- 2011-06-15 EC EC2011011134A patent/ECSP11011134A/es unknown
-
2012
- 2012-11-30 US US13/690,585 patent/US20130085266A1/en not_active Abandoned
-
2013
- 2013-04-19 JP JP2013088230A patent/JP5902122B2/ja active Active
-
2014
- 2014-02-02 IL IL230771A patent/IL230771A/en active IP Right Grant
-
2015
- 2015-06-12 US US14/737,488 patent/US9550837B2/en active Active
-
2016
- 2016-12-13 US US15/377,364 patent/US10023654B2/en active Active
-
2017
- 2017-03-10 CY CY20171100308T patent/CY1118896T1/el unknown
- 2017-06-16 NL NL300879C patent/NL300879I2/nl unknown
- 2017-06-19 CY CY2017021C patent/CY2017021I1/el unknown
- 2017-06-19 LT LTPA2017019C patent/LTC2358756I2/lt unknown
- 2017-06-21 LU LU00024C patent/LUC00024I2/en unknown
- 2017-06-21 FR FR17C1022C patent/FR17C1022I2/fr active Active
- 2017-06-27 NO NO2017029C patent/NO2017029I2/no unknown
- 2017-06-27 HU HUS1700029C patent/HUS1700029I1/hu unknown
- 2017-07-03 FI FIEP09793408.7T patent/FI2358756T4/fi active
- 2017-07-03 FI FIC20170031C patent/FIC20170031I1/fi unknown
-
2018
- 2018-06-04 US US15/996,773 patent/US10941210B2/en active Active
-
2021
- 2021-01-28 US US17/160,634 patent/US20210253735A1/en not_active Abandoned
-
2023
- 2023-04-05 US US18/296,265 patent/US20230340153A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP11011134A (es) | Anticuerpos humanos de alta afinidad contra pcsk9 | |
CY1123552T1 (el) | Θεραπειες συνδυασμου με χρηση μοριων προσδεσης psl και pcrv αντι- pseudomonas | |
CL2008003782A1 (es) | Anticuerpo bivalente bioespecifico que comprende la cadena ligera y pesada de un anticuerpo que se une a un primer antigeno donde el dominio ch3 se reemplaza por ch1, y la cadena ligera y pesada de un anticuerpo que se une a un segundo antigeno, en el que el dominio ch3 esta reemplazado por cl; metodo de preparacion; y composicion. | |
BR112014008382A2 (pt) | anticorpo especificamente ligando a epítope no domínio sema do c-met | |
ES2664972T3 (es) | Moléculas de unión anti-Psl de Pseudomonas y usos de las mismas | |
CY1116488T1 (el) | Αντισωματα anti-προπερδινης | |
PA8850101A1 (es) | Combinaciones antitumorales que contienen anticuerpos | |
AR069775A1 (es) | Anticuerpos bivalentes biespecificos | |
CL2013002161A1 (es) | Metodo para tratar enfermedad o afección en el que la expresión o la actividad de la proproteína convertasa subtilisina/kexina tipo 9 (pcsk9) ocasionan un impacto; anticuerpo o fragmento de unión al antígeno que se une específicamente a la proproteína convertasa subtilisina/kexina tipo 9 (pcsk9). | |
CL2008001656A1 (es) | Anticuerpo anti-c3b; composicion farmaceutica que lo comprende, y su uso para prevenir o tratar un trastorno asociado con el complemento; kit que lo contiene. | |
EA201101117A1 (ru) | Ингибиторы дпп-4 для лечения диабета у детей | |
UY33407A (es) | Anticuerpos específicos del factor gdf8 humano | |
EA201390929A1 (ru) | Антитела к pcsk9 и способы их применения | |
CL2012002428A1 (es) | Anticurpos de dominio (dab) que se une a cd 28 e inhibe la union de cd28 a cd80 y/o cd86 y no reacciona en forma cruzada con ctla4; uso del anticuerpo para tratar una enfermedad inmune o relacionada con un injerto; composicion farmaceutica que lo comprende. | |
BRPI0818765A8 (pt) | Polipeptídeo, anticorpo ou seu fragmento de ligação de antígeno, polinucleotídeo, célula hospedeira, vetor, composição, uso e método para produzir polipeptídeo | |
EA201000984A1 (ru) | Синтетические тритерпеноиды и способы их применения в лечении заболеваний | |
ECSP14001249A (es) | Inmunoenlazadores dirigidos contra el tnf | |
CL2012002884A1 (es) | Polipeptido que comprende un dominio decimo de fibronectina de tipo iii que se unen a la proteina covertasa subtilisina kexina tipo q ( pcsk9); composicion farmacéutica que comprende dicho polipeptido. | |
EA201100779A1 (ru) | Композиции антител к cxcr1 и способы их применения | |
BR112014007253A2 (pt) | uso de anticorpos que se ligam a il-1beta | |
CO6700864A2 (es) | Cuantificación y caracterización de alérgenos | |
BR112013000840A2 (pt) | método para aumentar o efeito de forma ativada potencializada de anticorpo para molécula endógena biológica, composição farmacêutica e uso de combinação de molécula biológica endógena com forma ativada potencializada de anticorpo para a sintase no endotelial. | |
AR087094A1 (es) | Formulaciones que estabilizan proteinas | |
EA200800144A1 (ru) | МОДИФИКАЦИИ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ | |
MY188372A (en) | High affinity human antibodies to pcsk9 |